Pharmacoeconomic analysis of treatment of Parkinson's disease
In the present pharmacoeconomic study was made a comparison of standard therapy of Parkinson disease with Stalevo. The cost-effectiveness analysis for this study was conducted; effectiveness of treatments was evaluated by DALY. Stalevo had shown advantages compared to standard therapy of Parkinson disease such as reduction of doses of levodopa and indirect costs and lower cost-effectiveness ratio. The cost-effectiveness ratio for Stalevo was 191 492 RUB for 1 DALY, than for standard therapy it was 258 326 RUB for 1 DALY.